Immune Reactions to CGRP Migraine Antibodies Are Rare and Usually Harmless
Anti-drug antibody formation against CGRP monoclonal antibodies for migraine ranges from <1% to 18%, with neutralizing antibodies even rarer, and adverse events from immunogenicity are uncommon.
Quick Facts
What This Study Found
ADA prevalence ranged from <1% to ~18% and neutralizing ADA from 0-12% across CGRP mAbs, with adverse events related to ADA formation rare across all four approved migraine antibodies.
Key Numbers
20 studies; 4 CGRP mAbs; ADA <1-18%; neutralizing 0-12%; adverse events rare
How They Did This
Review of immunogenicity data from 20 studies (5 per antibody) including Phase 2, Phase 3, and long-term extension studies of eptinezumab, erenumab, fremanezumab, and galcanezumab.
Why This Research Matters
Patients and clinicians considering long-term CGRP antibody therapy need to know whether the body will mount an immune reaction that could reduce drug effectiveness or cause side effects.
The Bigger Picture
As biologic therapies become standard care for chronic conditions like migraine, understanding immunogenicity is essential for long-term treatment planning. This review provides reassurance that immune reactions to CGRP antibodies are generally manageable and don't typically compromise treatment.
What This Study Doesn't Tell Us
Direct cross-study comparison is impossible due to lack of standardized immunogenicity assays. Long-term data (beyond trial durations) is limited. Individual patient risk factors for ADA development are not well characterized.
Questions This Raises
- ?Do ADAs explain why some patients stop responding to CGRP antibodies over time?
- ?Which patient factors predict higher immunogenicity risk?
- ?Would standardized ADA assays change the reported prevalence rates?
Trust & Context
- Key Stat:
- <1% to ~18% ADA rates Across four CGRP antibodies, with adverse events from immune reactions rare for all agents
- Evidence Grade:
- Comprehensive review of 20 clinical studies covering all four approved CGRP antibodies. Strong evidence base for immunogenicity assessment.
- Study Age:
- Published in 2021, reflecting early to moderate clinical experience with CGRP antibodies.
- Original Title:
- Immunogenicity of biologic therapies for migraine: a review of current evidence.
- Published In:
- The journal of headache and pain, 22(1), 3 (2021)
- Authors:
- Cohen, Joshua M, Ning, Xiaoping(2), Kessler, Yoel(2), Rasamoelisolo, Michele, Campos, Verena Ramirez, Seminerio, Michael J, Krasenbaum, Lynda J, Shen, Honglue, Stratton, Jennifer
- Database ID:
- RPEP-05323
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Will my body develop immunity against my CGRP migraine drug?
Some patients do develop anti-drug antibodies (up to 18%), but this rarely causes problems. Even neutralizing antibodies that could theoretically reduce drug effectiveness are uncommon (0-12%), and adverse events from these immune reactions are rare across all four approved CGRP antibodies.
Should I be tested for anti-drug antibodies while on CGRP therapy?
Routine ADA testing is not currently standard practice for migraine patients on CGRP antibodies. The clinical impact of ADAs appears to be minimal for most patients. If you're experiencing a loss of treatment effect, your doctor may consider immunogenicity as one possible explanation.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05323APA
Cohen, Joshua M; Ning, Xiaoping; Kessler, Yoel; Rasamoelisolo, Michele; Campos, Verena Ramirez; Seminerio, Michael J; Krasenbaum, Lynda J; Shen, Honglue; Stratton, Jennifer. (2021). Immunogenicity of biologic therapies for migraine: a review of current evidence.. The journal of headache and pain, 22(1), 3. https://doi.org/10.1186/s10194-020-01211-5
MLA
Cohen, Joshua M, et al. "Immunogenicity of biologic therapies for migraine: a review of current evidence.." The journal of headache and pain, 2021. https://doi.org/10.1186/s10194-020-01211-5
RethinkPeptides
RethinkPeptides Research Database. "Immunogenicity of biologic therapies for migraine: a review ..." RPEP-05323. Retrieved from https://rethinkpeptides.com/research/cohen-2021-immunogenicity-of-biologic-therapies
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.